The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies.

Non-melanoma skin cancers (NMSCs), particularly basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), are the most common malignancies in the Caucasian population. While localized disease has a high cure rate, advanced cases pose therapeutic challenges. The introduction of immune checkpoint inhibitors (ICIs) has revolutionized treatment; however, resistance and contraindications necessitate alternative strategies. Epidermal growth factor receptor (EGFR) inhibition, particularly with cetuximab, has emerged as a potential therapeutic option in cSCC. This review evaluates the role of cetuximab in NMSC, focusing on clinical efficacy, safety, and emerging therapeutic strategies. A literature search was conducted using PubMed and clinical trial databases to identify relevant studies on cetuximab in advanced cSCC and BCC. The review discusses its use as monotherapy, in combination with radiotherapy or chemotherapy, and in the post-ICI setting. Despite the dominance of ICIs in advanced cSCC, cetuximab remains a valuable option, particularly for patients with ICI failure or contraindications. Its role as a radiosensitizer and its potential combination with immunotherapy warrant further investigation. Future studies should clarify optimal sequencing and combination strategies to improve patient outcomes.